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ABSTRACT
Objective: The phase III GO-FORWARD study examined
the efficacy and safety of golimumab in patients with
active rheumatoid arthritis (RA) despite methotrexate
therapy.
Methods: Patients were randomly assigned in a
3 : 3 : 2 : 2 ratio to receive placebo injections plus
methotrexate capsules (group 1, n = 133), golimumab
100 mg injections plus placebo capsules (group 2,
n = 133), golimumab 50 mg injections plus metho-
trexate capsules (group 3, n = 89), or golimumab
100 mg injections plus methotrexate capsules (group 4,
n = 89). Injections were administered subcutaneously
every 4 weeks. The co-primary endpoints were the
proportion of patients with 20% or greater improvement in
the American College of Rheumatology criteria (ACR20) at
week 14 and the change from baseline in the health
assessment questionnaire-disability index (HAQ-DI) score
at week 24.
Results: The proportion of patients who achieved an
ACR20 response at week 14 was 33.1% in the placebo
plus methotrexate group, 44.4% (p=0.059) in the
golimumab 100 mg plus placebo group, 55.1%
(p=0.001) in the golimumab 50 mg plus methotrexate
group and 56.2% (p,0.001) in the golimumab 100 mg
plus methotrexate group. At week 24, median improve-
ments from baseline in HAQ-DI scores were 0.13, 0.13
(p=0.240), 0.38 (p,0.001) and 0.50 (p,0.001),
respectively. During the placebo-controlled portion of the
study (to week 16), serious adverse events occurred in
2.3%, 3.8%, 5.6% and 9.0% of patients and serious
infections occurred in 0.8%, 0.8%, 2.2% and 5.6%,
respectively.
Conclusion: The addition of golimumab to methotrexate
in patients with active RA despite methotrexate therapy
significantly reduced the signs and symptoms of RA and
improved physical function.
Clinical studies have demonstrated that treatment
with biological agents that target tumour necrosis
factor (TNF) improve manifestations of rheuma-
toid arthritis (RA).
1–10 These compounds have been
shown to provide greater benefit when combined
with methotrexate therapy than when each
agent or methotrexate is administered alone.
10–12
However, all currently available anti-TNFa
agents have differences in affinity, stability, solu-
bility, terminal half-life characteristics and dosing
regimens.
13–15
Golimumab is a human anti-TNFa monoclonal
antibody that was generated and affinity matured
in an in-vivo system. Golimumab has a high
affinity and specificity for human TNFa and
effectively neutralises TNFa bioactivity in vitro.
16
Results of an earlier phase II study of golimumab in
172 patients with active RA despite methotrexate
therapy demonstrated the efficacy of golimumab
given every 4 weeks by subcutaneous injection in
combination with methotrexate.
17 The clinical
effect was evident within 2 weeks of the first dose
and was sustained to 1 year. In this larger phase III
study, we evaluated the efficacy and safety of
golimumab in the treatment of patients with
active RA despite methotrexate therapy.
PATIENTS AND METHODS
This was a phase III, multicentre, randomised,
double-blind, placebo controlled trial. The study
included a double-blind controlled phase to week
52 and an open-label extension up to 5 years. In
this report, we present the results to week 24,
which include the co-primary endpoints at weeks
14 and 24. Patients were enrolled at 60 investiga-
tional sites in 12 countries: Argentina, Australia,
Canada, Chile, Germany, Hungary, Mexico, New
Zealand, Poland, South Korea, Taiwan and the
USA.
The study was conducted in accordance with the
Declaration of Helsinki and good clinical practices.
The protocol was reviewed and approved by each
site’s institutional review board or ethics commit-
tee. All patients provided written informed consent
before undergoing study-related procedures.
Patients
Study participants were 18 years of age or older,
had a diagnosis of RA according to the revised 1987
criteria of the American College of Rheumatology
(ACR)
18 for at least 3 months before screening, and
were to have been on a stable methotrexate dose of
15 mg/week or greater but 25 mg/week or less
during the 4-week period immediately preceding
screening. Patients were to have tolerated 15 mg/
week or greater of methotrexate for at least
3 months before screening. Patients were required
to have active RA, defined as four of more swollen
joints (out of 66 total) and four or more tender
joints (out of 68 total) and at least two of the
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Ann Rheum Dis 2009;68:789–796. doi:10.1136/ard.2008.099010 789following: (1) C-reactive protein (CRP) of 1.5 mg/dl or greater
(normal range 0–0.6 mg/dl) or erythrocyte sedimentation rate
(ESR) by the Westergren method of 28 mm/h or greater; (2) at
least 30 minutes of morning stiffness; (3) bone erosion deter-
mined by x ray and/or magnetic resonance imaging; or (4) anti-
cyclic citrullinated peptide antibody or rheumatoid factor positive
test results. Eligible patients had to have met the tuberculosis
screening criteria (supplemental material 1, available online only).
Patients who were using non-steroidal anti-inflammatory
drugs or other analgesics for RA had to be taking a stable dose
for at least 2 weeks before the first dose of study agent. Patients
who were taking oral corticosteroids had to have been receiving
a stable dose equivalent to 10 mg/day or less of prednisone for
at least 2 weeks before the first dose of study agent.
Patients were excluded from study participation if they had a
known hypersensitivity to human immunoglobulin proteins or
other components of golimumab. Any previous use of any anti-
TNF agent, rituximab, natalizumab or cytotoxic agents
excluded patients from study participation. In addition, patients
should not have received anakinra; disease-modifying antirheu-
matic drugs other than methotrexate; or intravenous, intra-
muscular, or intra-articular corticosteroids within 4 weeks
before the first dose of study agent or alefacept or efalizumab
within 3 months before the first dose of the study agent. A
complete list of inclusion and exclusion criteria is provided in
supplemental material 1 (available online only).
Study design
During a 4-week run-in period between screening and rando-
misation, all patients received study-supplied over-encapsulated
methotrexate capsules at their pre-study stable dose. Patients
were re-evaluated for study eligibility at the end of this 4-week
run-in period. Patients who still met the study criteria were
randomly assigned in a 3 : 3 : 2 : 2 ratio to receive: placebo
injections plus methotrexate (group 1), golimumab 100 mg
injections plus placebo capsules (group 2), golimumab 50 mg
injections plus methotrexate (group 3), or golimumab 100 mg
injections plus methotrexate (group 4).
Randomisation was stratified by investigational site and was
conducted using a telephone interactive voice response system.
All patients continued their initial stable doses of methotrexate
throughout the study without interruption except for patients
in group 2 who were switched from active methotrexate to
sham methotrexate capsules at randomisation without any
washout period before study entry.
At week 16, patients in groups 1, 2 or 3 with less than a 20%
improvement from baseline in both tender and swollen joint
counts had their study medication adjusted in a double-blind
fashion (ie, early escape). Patients in group 1 who met the
criteria for early escape began receiving active golimumab 50 mg
every 4 weeks and continued their stable dose of active
methotrexate. Patients in group 2 who met the criteria for
early escape had their sham methotrexate capsules replaced
with active methotrexate capsules at the same stable dose that
the patient had received at screening and continued to receive
injections of golimumab 100 mg every 4 weeks. Patients in
group 3 who met the criteria for early escape had their
golimumab dose increased from 50 mg to 100 mg every 4 weeks
and continued to receive their stable dose of active methotrex-
ate. Patients in group 4 had no adjustments made to their
subcutaneous or oral study medication.
Treatments
Centocor Research and Development, Inc supplied all study
medication. Golimumaband placebo were supplied assterileliquid
for subcutaneous injection. Placebo injections contained the same
solution as active golimumab but did not contain the monoclonal
antibody. Active methotrexate and placebo methotrexate were
suppliedasidenticalopaquecapsules.Injectionswereadministered
Figure 1 Disposition of patients during the study. MTX, methotrexate; SC, subcutaneous.
Extended report
790 Ann Rheum Dis 2009;68:789–796. doi:10.1136/ard.2008.099010every 4 weeks and each patient received two injections per dose
(0.5 ml and 1.0 ml syringes) to maintain the blind.
Evaluations
Response to treatment was assessed using the ACR response
criteria (ACR20/50/70).
19 ACR-N
92 0 was also calculated. The
disease activity score in 28 joints (DAS28)
21 was calculated
separately using both CRP and ESR. The European League
Against Rheumatism (EULAR) response was calculated accord-
ing to previously described methods,
22 and DAS28 remission
was defined as a score of less than 2.6.
22
An independent assessor designated at each study centre
performed all joint assessments. The joint assessor had no other
contact with the patient, was not the treating physician and
was not permitted to review patient medical records, case report
forms, or previous joint counts during the study.
The health assessment questionnaire disability index (HAQ-
DI) was used to evaluate physical function.
23 The minimum
clinically important difference in HAQ-DI score has previously
been defined as a reduction of 0.22 or greater.
24 We evaluated the
proportions of patients with a reduction from baseline in HAQ-
DI of 0.25 or greater as a more conservative estimation of the
minimum clinically important change.
Serum samples taken at baseline and week 24 were assessed
for the presence of antibodies to golimumab using a previously
described assay.
17 The presence of the study agent in the serum
interferes with the detection of antibodies to the study agent in
these types of assays.
11 25
Sample size calculation
Assuming 55% or more of patients in groups 3 and 4 and
35% of patients in group 1 would achieve an ACR20
response, a sample size of 120 patients in group 1 and 80
patients in groups 3 and 4 was required to achieve greater
than 90% power (two-sided x
2, a = 0.05). Assuming 55% of
patients in group 2 and 35% of patients in group 1 would
achieve an ACR20 response, a sample size of 120 patients in
both groups 1 and 2 was needed to achieve greater than 85%
power (two-sided x
2 test, a = 0.05). This sample size would
also provide greater than 90% power to detect a difference in
the change from baseline in HAQ-DI score between treat-
ment groups (two-sided t test on the van der Waerden
normal scores, a = 0.05), assuming an improvement from
baseline in HAQ-DI of 20.21 for group 1, 20.47 for group 3
and 20.39 for group 4.
Table 1 Demographic and baseline disease characteristics
Characteristic
Group 1 Group 2
Golimumab + methotrexate
Group 3 Group 4
Groups 3 and 4 combined
Placebo +
methotrexate
Golimumab 100 mg
+ placebo 50 mg 100 mg
Patients randomly assigned 133 133 89 89 178
Sex, n (%) women 109 (82.0%) 105 (78.9%) 72 (80.9%) 72 (80.9%) 144 (80.9%)
Age, years 52.0 (42.0 to 58.0) 51.0 (42.0 to 59.0) 52.0 (43.0 to 57.0) 50.0 (45.0 to 56.0) 51.0 (44.0 to 57.0)
Disease duration, years 6.5 (3.1 to 11.9) 5.9 (2.4 to 12.2) 4.50 (2.1 to 9.7) 6.70 (2.4 to 14.3) 5.3 (2.1 to 12.3)
No of swollen joints, 0–66 12.0 (8.0 to 19.0) 11.0 (8.0 to 17.0) 13.0 (8.0 to 22.0) 12.0 (8.0 to 18.0) 12.5 (8.0 to 18.0)
No of tender joints, 0–68 21.0 (14.0 to 34.0) 22.0 (14.0 to 32.0) 26.0 (16.0 to 39.0) 23.0 (15.0 to 33.0) 24.5 (15.0 to 37.0)
Anti-CCP antibodies 107 (80.5%) 106 (79.7%) 72 (80.9%) 68 (76.4%) 140 (78.7%)
Rheumatoid factor 108 (81.2%) 111 (83.5%) 77 (86.5%) 75 (84.3%) 152 (85.4%)
Patient assessment of pain,
VAS, 0–10 cm
5.70 (3.60 to 7.50) 6.00 (4.50 to 7.40) 6.10 (4.70 to 7.70) 6.40 (4.60 to 8.00) 6.35 (4.60 to 8.00)
Patient global assessment of
disease activity, VAS, 0–10 cm
5.30 (3.70 to 7.20) 5.60 (3.60 to 7.40) 6.00 (3.80 to 7.90) 5.90 (4.10 to 7.70) 5.95 (3.90 to 7.80)
Evaluator global assessment of
disease activity, VAS, 0–10 cm
5.65 (4.30 to 6.85) 5.80 (4.40 to 6.80) 6.10 (5.10 to 7.10) 6.10 (4.30 to 7.00) 6.10 (4.70 to 7.10)
HAQ-DI, 0–3 1.250 (0.750 to 1.750) 1.375 (0.875 to 1.8750) 1.375 (1.000 to 1.875) 1.375 (0.875 to 1.875) 1.375 (0.875 to 1.875)
CRP, mg/dl 0.80 (0.30 to 2.00) 0.90 (0.40 to 2.50) 1.00 (0.40 to 2.80) 0.90 (0.40 to 2.40) 0.95 (0.40 to 2.40)
DAS28 using CRP 4.860 (4.194 to 5.480) 4.803 (4.151 to 5.558) 5.100 (4.060 to 5.651) 4.902 (4.320 to 5.521) 4.931 (4.174 to 5.598)
DAS28 using ESR 6.111 (5.260 to 6.574) 6.013 (5.198 to 6.800) 6.105 (5.366 to 6.940) 5.905 (5.292 to 6.805) 6.008 (5.330 to 6.843)
Methotrexate dose, mg/week 15.0 (15.0 to 20.0) 15.0 (15.0 to 20.0) 15.0 (15.0 to 20.0) 15.0 (15.0 to 20.0) 15.0 (15.0 to 20.0)
Duration of previous
methotrexate use, years
,1 33 (24.8%) 30 (22.6%) 20 (22.5%) 17 (19.1%) 37 (20.8%)
>1t o,3 30 (22.6%) 41 (30.8%) 32 (36.0%) 31 (34.8%) 63 (35.4%)
>3 68 (51.1%) 62 (46.6%) 37 (41.6%) 40 (44.9%) 77 (43.3%)
Patients taking corticosteroids 87 (65.4%) 90 (67.7%) 67 (75.3%) 62 (69.7%) 129 (72.5%)
Prednisone or equivalent dose,
mg/day
7.3 (5.0 to 10.0) 7.5 (5.0 to 10.0) 7.5 (5.0 to 10.0) 7.5 (5.0 to 10.0) 7.5 (5.0 to 10.0)
Patients with previous use of
DMARD other than
methotrexate
94 (70.7%) 101 (75.9%) 70 (78.7%) 67 (75.3%) 137 (77.0%)
Patients who required treatment
for latent tuberculosis at
baseline*
31 (23.3%) 26 (19.5%) 18 (20.2%) 17 (19.1%) 35 (19.7%)
Values are n (%) or median (interquartile range). CCP, cyclic citrullinated peptide; CRP, C-reactive protein; DAS28, disease activity score in 28 joints; ESR, erythrocyte sedimentation
rate; DMARD, disease-modifying antirheumatic drug; HAQ-DI, health assessment questionnaire disability index; VAS, visual analogue scale. *Treatment usually consisted of
isoniazid.
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There were two co-primary endpoints: the proportion of
patients achieving an ACR20 response at week 14 and the
improvement from baseline in HAQ-DI score at week 24. A
two-sided x
2 test was used to analyse the ACR20 data and a
two-sided analysis of variance on the van der Waerden
normal scores was used to analyse the HAQ-DI data; both
were conducted at a significance level of a = 0.05. The co-
primary endpoints were analysed sequentially (ACR20
response at week 14 first and HAQ-DI at week 24 second)
to maintain an overall type I error rate of 0.05. Additional
details regarding statistical testing of the primary endpoint
and data handling guidelines are provided in supplemental
material 2 (available online only).
RESULTS
Data were collected between 19 December 2005 and 17
September 2007. A total of 444 patients was randomly assigned
to study treatment (fig 1). The treatment groups were generally
well balanced with regard to baseline demographic and disease
characteristics (table 1).
Table 2 Efficacy results at weeks 14 and 24
Assessment
Group 1 Group 2
Golimumab + methotrexate
Group 3 Group 4
Groups 3 and 4 combined
Placebo +
methotrexate
Golimumab 100 mg
+ placebo 50 mg 100 mg
Patients randomly assigned 133 133 89 89 178
Primary endpoints
ACR20 at week 14 44 (33.1%) 59 (44.4%) 49 (55.1%) 50 (56.2%) 99 (55.6%)
p Value 0.059 0.001 ,0.001 ,0.001
Improvement from baseline in
HAQ-DI at week 24
20.13 (20.38 to 0.13) 20.13 (20.63 to 0.25) 20.38 (20.75 to 20.13) 20.50 (20.75 to 20.13) 20.44 (20.75 to 20.13)
p Value 0.240 ,0.001 ,0.001 ,0.001
Secondary endpoints
Week 14
ACR50 13 (9.8%) 27 (20.3%) 31 (34.8%) 26 (29.2%) 57 (32.0%)
p Value 0.016 ,0.001 ,0.001 ,0.001
ACR70 5 (3.8%) 10 (7.5%) 12 (13.5%) 8 (9.0%) 20 (11.2%)
p Value 0.184 0.008 0.104 0.016
ACR90 1 (0.8%) 1 (0.8%) 2 (2.2%) 0 (0.0%) 2 (1.1%)
p Value 1.000 0.344 0.412 0.740
ACR-N 0.00 (228.60 to 25.50) 10.50 (211.80 to 42.60) 28.20 (0.00 to 60.00) 25.00 (0.00 to 54.50) 27.30 (0.00 to 56.30)
p Value 0.042 ,0.001 ,0.001 ,0.001
Improvement from baseline in
HAQ-DI
20.13 (20.38 to 0.13) 20.25 (20.63 to 0.13) 20.38 (20.75 to 20.13) 20.38 (20.63 to 20.13) 20.38 (20.75 to 20.13)
p Value 0.097 ,0.001 ,0.001 ,0.001
EULAR responders (DAS28
calculated using ESR)
59 (44.4%) 79 (59.4%) 63 (70.8%) 67 (75.3%) 130 (73.0%)
p Value 0.014 ,0.001 ,0.001 ,0.001
DAS28 (ESR) remission 2 (1.5%) 11 (8.3%) 14 (15.7%) 16 (18.0%) 30 (16.9%)
p Value 0.010 ,0.001 ,0.001 ,0.001
Week 24
ACR20 37 (27.8%) 47 (35.3%) 53 (59.6%) 53 (59.6%) 106 (59.6%)
p Value 0.187 ,0.001 ,0.001 ,0.001
ACR50 18 (13.5%) 26 (19.5%) 33 (37.1%) 29 (32.6%) 62 (34.8%)
p Value 0.187 ,0.001 ,0.001 ,0.001
ACR70 7 (5.3%) 15 (11.3%) 18 (20.2%) 13 (14.6%) 31 (17.4%)
p Value 0.075 ,0.001 0.017 0.001
ACR90 1 (0.8%) 3 (2.3%) 5 (5.6%) 2 (2.2%) 7 (3.9%)
p Value 0.314 0.028 0.344 0.080
ACR-N 0.00 (225.00 to 22.20) 0.00 (225.40 to 37.10) 36.60 (0.00 to 60.40) 28.60 (0.00 to 55.30) 35.70 (0.00 to 60.00)
p Value 0.151 ,0.001 ,0.001 ,0.001
EULAR responders (DAS28
calculated using ESR)
56 (42.1%) 69 (51.9%) 64 (71.9%) 68 (76.4%) 132 (74.2%)
p Value 0.110 ,0.001 ,0.001 ,0.001
DAS28 (ESR) remission 8 (6.0%) 16 (12.0%) 18 (20.2%) 20 (22.5%) 38 (21.3%)
p Value 0.087 0.001 ,0.001 ,0.001
DAS28 (ESR) sustained
remission*
1 (0.8%) 8 (6.3%) 9 (10.2%) 10 (11.9%) 19 (11.0%)
p Value 0.018 0.001 ,0.001 ,0.001
Values are n (%) of patients achieving an endpoint or median (interquartile range) improvement from baseline. *Patients who achieved disease activity score in 28 joints (DAS28)
remission at week 14 and maintained it at week 24 were considered to have achieved sustained remission. ACR, American College of Rheumatology response criteria; ESR,
erythrocyte sedimentation rate; EULAR, European League Against Rheumatism; HAQ-DI, health assessment questionnaire disability index.
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Thirty-three per cent of patients in group 1 achieved an ACR20
response at week 14 compared with 55.6% (p,0.001) in the
combined groups 3 and 4, representing 55.1% (p=0.001) in
group 3 and 56.2% (p,0.001) in group 4 (table 2). The
proportion of ACR20 responders in group 2 (44.4%) was not
statistically significantly different from that of group 1 (33.1%)
at the a = 0.05 level (p=0.059). Four patients (3.0%) in group
1, four patients (3.0%) in group 2, three patients (3.4%) in group
3 and one patient (1.1%) in group 4 were considered not to have
achieved the primary endpoint because they met the prespeci-
fied treatment failure criteria (see supplemental material 2,
available online only).
At week 24, patients in the combined groups 3 and 4 also
showed significantly greater improvement in the median HAQ-
DI score (20.44, p,0.001) compared with group 1 (20.13),
with improvements of 20.38 (p=0.001) in group 3 and 20.50
(p,0.001) in group 4 (table 2). No difference in the improve-
ment in median HAQ-DI score was observed between group 2
and group 1 (20.13; p=0.240). Overall, 38.6% of patients in
group 1, 45.3% of patients in group 2 (p=0.276), 68.2% of
patients in group 3 (p,0.001) and 72.1% of patients in group 4
(p,0.001) achieved a reduction in HAQ-DI score of 0.25 or
greater.
Results of the secondary endpoints supported those of the co-
primary endpoints (table 2 and see supplemental table 1,
available online only). ACR20 responses were observed in
groups 3 and 4 as early as the first assessment at week 4 and
generally increased to week 24 (fig 2). The proportions of
patients achieving ACR20 responses in groups 1 and 2 peaked at
week 14 and subsequently decreased slightly. Significantly
greater proportions of patients in the combined groups 3 and
4 also achieved EULAR response, DAS28 remission, and ACR50
and ACR70 responses at weeks 14 and 24 compared with group
1 (table 2).
The co-primary endpoints were evaluated in subgroups of
patients divided by geographical region (supplemental table 2,
available online only). The proportions of patients with ACR20
responses at week 14 were greater in the combined groups 3 and
4 compared with group 1 in Europe–Australia–New Zealand,
North America and Asia but not in Latin America. The placebo
response rate in Latin America was greater (68.2%) than that of
the other regions (25.4%, 22.6% and 33.3% for Europe–
Australia–New Zealand, North America and Asia, respectively).
Similar patterns were observed for the improvement from
baseline to week 24 in HAQ-DI score. When data from Latin
American sites were excluded from the analysis, 26.1% of
patients in group 1 had an ACR20 response compared with
41.8% of patients in group 2 (p=0.014), 55.6% of patients in
group 3 (p,0.001) and 54.2% of patients in group 4 (p,0.001).
Overall, 41 patients (31.6%), 36 patients (27.1%) and 15
patients (16.9%) in groups 1, 2 and 3, respectively, met the early
escape criteria at week 16 (fig 1). Of these, 17 patients (41.5%),
seven patients (19.4%) and three patients (20.0%), respectively,
achieved an ACR20 response at week 24. Of the 14 patients
(15.7%) in group 4 (100 mg plus methotrexate group) who met
the criteria for early escape at week 16 without any dose
adjustments, four patients (28.6%) had an ACR20 response at
week 24.
Safety
To week 16, before patients had the opportunity for early
escape, the proportions of patients with adverse events were
60.9% in group 1, 63.2% in group 2, 68.5% in group 3 and 69.7%
in group 4 (table 3). Serious adverse events occurred in 2.3%,
3.8%, 5.6% and 9.0% of patients, respectively.
Safety results to week 24 are presented as the number of
events per patient-year to account for patients who entered
early escape or discontinued treatment before week 24 (table 4).
The numbers of serious adverse events and serious infections per
patient-year were greater in group 4 than in groups 1, 2 or 3;
however, the 95% CI were wide and overlapping.
One patient died during the study. The patient was assigned
to group 2 and received study treatments at baseline and week
4. The patient developed nausea, diarrhoea and dehydration and
was hospitalised on study day 56 (week 8), developed an ileus
and aspiration pneumonia and subsequently died from sepsis on
study day 69 (week 9).
Table 3 Summary of adverse events during the placebo-controlled phase of the study through week 16
(before early escape)
Assessment
Group 1 Group 2
Golimumab + methotrexate
Group 3 Group 4 Groups 3 and 4
combined
Placebo +
methotrexate
Golimumab 100 mg
+ placebo 50 mg 100 mg
Patients treated 133 133 89 89 178
Average duration of follow-up
(weeks)
15.9 16.0 16.1 15.9 16.0
Average exposure (no of
administrations)
3.9 4.0 3.9 3.9 3.9
Patients with one or more
adverse events
81 (60.9%) 84 (63.2%) 61 (68.5%) 62 (69.7%) 123 (69.1%)
Patients with one or more serious
adverse event
3 (2.3%) 5 (3.8%) 5 (5.6%) 8 (9.0%) 13 (7.3%)
Patients with one or more
infection
32 (24.1%) 40 (30.1%) 25 (28.1%) 25 (28.1%) 50 (28.1%)
Patients with one or more serious
infections
1 (0.8%) 1 (0.8%) 2 (2.2%) 5 (5.6%) 7 (3.9%)
Patients with one or more
injection-site disorders
3 (2.3%) 4 (3.0%) 4 (4.5%) 4 (4.5%) 8 (4.5%)
Patients with one or more
malignancies
0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (1.1%) 1 (1.1%)
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with latent tuberculosis but entered the study while
receiving treatment for latent tuberculosis (usually isoniazid,
table 1). None of these patients, or any other patients,
developed active tuberculosis. No patients had opportunistic
infections. A total of 12 patients had serious infections to
week 24 (table 4), including the previously mentioned patient
who died from sepsis.
Four patients had malignancies, including a patient in group 1
with basal cell cancer, a patient in group 2 with squamous cell
skin cancer, a patient in group 2 with basal cell cancer and a
patient in group 4 with breast cancer.
Table 4 Summary of adverse events to week 24
Assessment
Group 1 Group 2 Group 3 Group 4
Placebo +
methotrexate (n = 134)
Golimumab 100 mg +
placebo (n = 133)
Golimumab 50 mg +
methotrexate (n = 212)
Golimumab 100 mg +
methotrexate (n = 105)
n (%)
Events per
patient-year n (%)
Events per
patient-year n (%)
Events per
patient-year n (%)
Events per
patient-year
Any adverse event 89 (66.4%) 4.72 (4.16 to 5.33) 98 (73.7%) 2.74 (2.45 to 3.05) 87 (41.0%) 1.75 (1.53 to 1.99) 78 (74.3%) 2.82 (2.48 to 3.19)
Serious adverse
events
5 (3.7%) 0.09 (0.03 to 0.21) 8 (6.0%) 0.11 (0.06 to 0.19) 9 (4.2%) 0.08 (0.04 to 0.14) 13 (12.4%) 0.18 (0.10 to 0.30)
Any infection 37 (27.6%) 1.16 (0.89 to 1.48) 50 (37.6%) 0.71 (0.57 to 0.88) 34 (16.0%) 0.36 (0.27 to 0.48) 39 (37.1%) 0.79 (0.62 to 1.00)
Serious infections 1 (0.7%) 0.02 (,0.01 to 0.10) 4 (3.0%) 0.05 (0.02 to 0.11) 2 (0.9%) 0.02 (,0.01 to 0.06) 5 (4.8%) 0.08 (0.03 to 0.17)
Cellulitis 0 (0.0%) 0.00 (0.00 to 0.06) 0 (0.0%) 0.00 (0.00 to 0.03) 1 (0.5%) 0.01 (,0.01 to 0.04) 1 (1.0%) 0.01 (,0.01 to 0.06)
Sepsis 0 (0.0%) 0.00 (0.00 to 0.06) 2 (1.5%) 0.02 (,0.01 to 0.06) 0 (0.0%) 0.00 (0.00 to 0.02) 2 (1.9%) 0.02 (,0.01 to 0.08)
UTI 1 (0.7%) 0.02 (,0.01 to 0.10) 0 (0.0%) 0.00 (0.00 to 0.03) 0 (0.0%) 0.00 (0.00 to 0.02) 2 (1.9%) 0.02 (,0.01 to 0.08)
Bacterial arthritis 0 (0.0%) 0.00 (0.00 to 0.06) 0 (0.0%) 0.00 (0.00 to 0.03) 0 (0.0%) 0.00 (0.00 to 0.02) 1 (1.0%) 0.01 (,0.01 to 0.06)
Lower RTI 0 (0.0%) 0.00 (0.00 to 0.06) 0 (0.0%) 0.00 (0.00 to 0.03) 0 (0.0%) 0.00 (0.00 to 0.02) 1 (1.0%) 0.01 (,0.01 to 0.06)
SC abscess 0 (0.0%) 0.00 (0.00 to 0.06) 0 (0.0%) 0.00 (0.00 to 0.03) 1 (0.5%) 0.01 (,0.01 to 0.04) 0 (0.0%) 0.00 (0.00 to 0.03)
Colitis 0 (0.0%) 0.00 (0.00 to 0.06) 1 (0.8%) 0.01 (,0.01 to 0.05) 0 (0.0%) 0.00 (0.00 to 0.02) 0 (0.0%) 0.00 (0.00 to 0.03)
Diarrhoea 0 (0.0%) 0.00 (0.00 to 0.06) 1 (0.8%) 0.01 (,0.01 to 0.05) 0 (0.0%) 0.00 (0.00 to 0.02) 0 (0.0%) 0.00 (0.00 to 0.03)
Infective arthritis 0 (0.0%) 0.00 (0.00 to 0.06) 1 (0.8%) 0.01 (,0.01 to 0.05) 0 (0.0%) 0.00 (0.00 to 0.02) 0 (0.0%) 0.00 (0.00 to 0.03)
Skin laceration 0 (0.0%) 0.00 (0.00 to 0.06) 1 (0.8%) 0.01 (,0.01 to 0.05) 0 (0.0%) 0.00 (0.00 to 0.02) 0 (0.0%) 0.00 (0.00 to 0.03)
Injection-site reactions 4 (3.0%) 0.11 (0.04 to 0.24) 10 (7.5%) 0.12 (0.06 to 0.20) 5 (2.4%) 0.08 (0.04 to 0.14) 5 (4.8%) 0.07 (0.03 to 0.15)
Malignancies 1 (0.7%) 0.02 (,0.01 to 0.10) 2 (1.5%) 0.02 (,0.01 to 0.06) 0 (0.0%) 0.00 (0.00 to 0.02) 1 (1.0%) 0.01 (,0.01 to 0.06)
Values are n (%) of patients having an event or number of events per patient year (95% CI). Events were categorised by the actual treatment the patient was receiving at the time of
the event. Total numbers of patients in each column are the numbers of patients who received that treatment at any time to week 24. Therefore, patients who entered early escape
were counted in more than one column. RTI, respiratory tract infection; SC, subcutaneous; UTI, urinary tract infection.
Figure 2 ACR20, ACR50, ACR70 and ACR90 responses to week 24. Patients who entered early escape at week 16 were considered to be non-
responders at all subsequent time points. ACR, American College of Rheumatology; MTX, methotrexate.
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were primarily mild in intensity and consisted most often of
injection-site erythema, bruising, or warmth. No injection site
reactions were considered to be severe or serious, and no
patients discontinued study treatment because of injection-site
reactions.
Antinuclear antibodies were observed in similar proportions
between the combined groups 3 and 4 (12.2%) and group 1
(14.9%) at week 14, whereas the proportion was greater for
patients in group 2 (29.3%) compared with groups 3 or 4 (5.7%
and 17.9%, respectively). No patients demonstrated symptoms
that would be consistent with lupus-like syndrome.
Overall, five of 236 patients with evaluable samples (2.1%)
had antibodies to golimumab at week 24. All of the patients
were from group 2. Two of the patients had received
golimumab 100 mg plus placebo without early escape and three
of the patients had entered early escape to golimumab 100 mg
plus methotrexate. Two of the five patients (40%) achieved an
ACR20 response at week 24 and one patient (20%) achieved an
ACR50 response. None of the patients with antibodies to
golimumab had an injection-site reaction.
DISCUSSION
We evaluated the effect of subcutaneous golimumab injections
every 4 weeks with or without background methotrexate on
the signs and symptoms of RA after 24 weeks in patients with
active disease despite treatment with methotrexate. The
combination of golimumab and methotrexate was superior to
either golimumab or methotrexate alone in improving the signs
and symptoms of RA and physical function. This is consistent
with the results of previous studies in which anti-TNF agents
were evaluated alone or in combination with methotrexate.
10 12
No clear difference in the efficacy of the two golimumab dose
groups that included concomitant methotrexate was evident.
Patients who received golimumab without methotrexate also
showed some evidence of benefit (eg, ACR50), but the
proportion of patients with an ACR20 response was not
statistically significantly greater than that observed for patients
who received methotrexate alone.
The baseline characteristics of the study population indicate
that patients had moderately to severely active RA. However,
patients in this study had shorter disease duration, fewer tender
and swollen joints, better physical function and lower CRP
levels than those in previous studies of biological agents in
patients with active RA despite methotrexate therapy.
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The less restrictive entry criteria in our study (eg, tender and
swollen joint counts and CRP) may have allowed for a broader
patient population. Recent data suggest that baseline disease
activity levels in patients who receive TNFa inhibitors in actual
clinical practice have decreased since these drugs first became
available.
27–29 The lower disease activity in our study cohort may
thus be reflective of this overall reduction in the disease activity
of patients in actual clinical practice. The shorter disease
duration of patients in our study cohort may also reflect an
increased tendency to treat patients with anti-TNF agents
earlier in their disease course.
Patients who received placebo plus methotrexate (group 1)
showed a greater than expected improvement in measures of
disease activity relative to previous anti-TNF studies of patients
with active RA despite methotrexate treatment.
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patients in our study also had exposure to methotrexate for
.1 year compared with patients in the previous trials (eg, the
ATTRACT study population),
1 providing additional evidence
that patients are now being treated with anti-TNF therapy
earlier in their disease course. Some patients who received
methotrexate for shorter durations may not have reached the
maximum benefit from methotrexate therapy before entering
the study and may have continued to improve during the study,
which would have inflated the number of ACR20 responders in
group 1. Greater treatment compliance in the context of a
clinical trial, in which methotrexate is provided at no cost to
patients and doses are monitored and tracked, may also have
contributed to this trend. The disproportionately high ACR20
responses (68%) among patients in group 1 from the Latin
American countries could also have contributed to this result.
Whereas the response rates with golimumab alone (group 2)
seemed to be adequate, clinically relevant and similar to those
observed with other anti-TNFa agents alone,
30 they were not
statistically significantly greater than methotrexate alone in this
patient population. The high response rate in group 1 must be
considered when interpreting these results. Another contribut-
ing factor may have been the unique design of this study that
did not include a washout period. A washout period was
omitted for clinical and ethical reasons, particularly given the
recent advances in treatment strategies of RA and the
availability of effective therapies. Patients with active RA
would have gone untreated during a washout period, which
could have increased their risk of developing irreversible joint
damage. All patients in groups 1, 3 and 4 thus continued
methotrexate treatment without interruption. For patients in
group 2, methotrexate was stopped when golimumab was
started and patients received sham methotrexate capsules.
Patients in this group whose disease was partly controlled by
methotrexate (while still meeting the study entry criteria)
would have been likely to experience worsening of disease
activity after discontinuing methotrexate. Therefore, this group
may have been at a disadvantage compared with the groups
who continued methotrexate in terms of showing an improve-
ment in efficacy parameters compared with baseline.
Golimumab was generally well tolerated with no unexpected
safety issues, even though many of the study sites were in
regions in which tuberculosis is endemic. Approximately 20% of
the patients had latent tuberculosis at screening and entered the
study receiving isoniazid (or other therapies for latent tubercu-
losis). None of these patients developed active tuberculosis.
Injection-site reactions were uncommon, occurring in
approximately 5% of patients who received golimumab at any
time. These reactions were generally mild or moderate and
consisted primarily of erythema; none led to discontinuation of
the study agent.
Patients in the golimumab groups had greater incidences of
infections than those in the methotrexate-alone group. Also,
patients in the 100 mg golimumab plus methotrexate group had
greater incidences of serious adverse events and serious infections
than those in the other groups. One patient who received
golimumab 100 mg alone died because of a serious infection. No
opportunistic infections or cases of tuberculosis were observed.
The observed incidence of antibodies to golimumab was too low
to evaluate their effect on clinical efficacy and safety.
In conclusion, the addition of golimumab injections every
4 weeks to methotrexate in patients with active RA signifi-
cantly reduced the signs and symptoms of RA and improved
physical function. The safety profile of golimumab was
generally consistent with what is expected for an anti-TNFa
agent. However, the study was not powered to assess adverse
events; therefore, definitive conclusions about safety cannot be
drawn. This study will continue to assess the long-term efficacy
and safety of golimumab.
Extended report
Ann Rheum Dis 2009;68:789–796. doi:10.1136/ard.2008.099010 795Acknowledgements: The authors would like to thank the patients, investigators and
study personnel who made this trial possible. Scott Newcomer, MS of Centocor Ortho
Biotech Services LLC, assisted in preparing the manuscript.
Funding: This study was funded by Centocor Research and Development, Inc, a
wholly owned subsidiary of Johnson&Johnson, Inc and Schering Plough Research
Institute, Inc.
Competing interests: Declared. ECK, MCG, LK, STH, PCM, JP, SCB and WP (or their
institutions) have received research grants from Centocor and/or Schering-Plough. LK
and ECK have received consulting fees from Centocor and/or Schering-Plough. ECH,
JZ, SV, ZW and MUR are employees of Centocor Research and Development, Inc and
own stock and/or stock options in Johnson&Johnson, Inc. MW is an employee of and
owns stock in Schering-Plough Research Institute, Inc.
Ethics approval: The protocol was reviewed and approved by each site’s institutional
review board or ethics committee.
Patient consent: Obtained.
The following investigators participated in the GO-FORWARD study: Argentina:
Alejandro Alvarellos (Co ´rdoba), Alejandra Magdelena Babinin (Co ´rdoba), Juan Carlos
Barreira (Cuidad Autonoma de Buenos Aires), Alberto Berman (Tucman), Maria Alicia
La ´zaro (Buenos Aires), Ingrid Strusberg (Co ´rdoba), Guillermo Alberto Tate (Buenos
Aires), Osvaldo Hu ¨bscher (Cuidad Autonoma de Buenos Aires), Bernardo Antonio Pons
Estel (Santa Fe ´); Australia: Stephen Hall (Malvern, VIC), Geoffrey Owen Littlejohn
(Clayton, VIC), Peter Thomas Nash (Maroochydore and Cotton Tree, QLD); Canada:
Christopher Atkins (Victoria, BC), Andre ´ Beaulieu (Ste-Foy, QC), Alfred Cividino
(Hamilton, ON), Edward Keystone (Toronto, ON), Majed Khraishi (St John’s, NL),
Robert McKendry (Ottawa, ON); Chile: Pedro Claudio Miranda Cabezas (Santiago), Ana
Flores Torterolo (Rancagua), Irmgadt Annelise Goecke (Santiago), Maria Loreto
Massardo Vega (Santiago), Juan Pablo Riedemann Gonzalez (Temuco); Germany:
Holm Ha ¨ntzschel (Leipzig), Rolf W Hauer (Berlin), Gunther Neeck (Rostock), Andrea
Rubbert (Ko ¨ln), Ju ¨rgen Wollenhaupt (Hamburg), Reinhold Ernst Schmidt and Henning
Zeidler (Hanover); Hungary: La ´szlo ´ Hodinka (Budapest); Mexico: Jorge Antonio
Esquivel Valerio (Monterrey, NL); New Zealand: Daniel Wai Tho Ching (Timaru), Nicola
Dalbeth (Auckland), Peter Brian Barrie Jones (Rotorua); Poland: Jan Brzezicki (Elblag),
Marek Stefan Brzosko (Szczecin), Zbigniew Adam Mencel (Kalisz), Anna Fillipowicz-
Sosnowska (Warszawa), Hanna Chwalin ´ska-Sadowska (Warszawa), Jacek Andrzej
Pazdur (Warszawa); South Korea: Sang Cheol Bae (Seoul), Hyun Ah Kim (Kyunggi-do),
Sung II Kim (Seo-Gu), Choong Ki Lee (Nam-gu Daegu), Soo Kon Lee (Seoul), Yeong
Wook Song (Seoul); Republic of China: Tien-Tsai Cheng (Taiwan); USA: Antony Hou
and Eugene P Boling (Upland, CA), Richard D Brasington, Jr (St Louis, MO), Melvin A
Churchill, Jr (Lincoln, NE), Gino DiVittorio (Mobile, AL), John E Ervin (Kansas City, MO),
Mark Genovese (Palo Alto, CA), Mitchell Lowenstein (Palm Harbor, FL), Michael
Miniter (Moline, IL), Frederick T Murphy (North Duncansville, PA), William Palmer
(Omaha, NE), Irene Tong (Pasadena, CA), Yong Tsai (Ormond Beach, FL), Christopher
Wise (Richmond, VA).
REFERENCES
1. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab
(chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in
rheumatoid arthritis patients receiving concomitant methotrexate: a randomised
phase III trial. ATTRACT Study Group. Lancet 1999;354:1932–9.
2. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al.
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor
Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
N Engl J Med 2000;343:1594–602.
3. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, et al.
Sustained improvement over two years in physical function, structural damage, and
signs and symptoms among patients with rheumatoid arthritis treated with infliximab
and methotrexate. Arthritis Rheum 2004;50:1051–65.
4. St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al.
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a
randomized, controlled trial. Arthritis Rheum 2004;50:3432–43.
5. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et
al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody,
for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate:
the ARMADA trial. Arthritis Rheum 2004;48:35–45.
6. Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, et al.
Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and
concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis:
results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol
2003;30:2563–71.
7. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al.
Radiographic, clinical, and functional outcomes of treatment with adalimumab (a
human anti-tumor necrosis factor monoclonal antibody) in patients with active
rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized,
placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400–11.
8. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ,
et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann
Intern Med 1999;130:478–86.
9. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al.
A comparison of etanercept and methotrexate in patients with early rheumatoid
arthritis. N Engl J Med 2000;343:1586–93.
10. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al.
Therapeutic effect of the combination of etanercept and methotrexate compared with
each treatment alone in patients with rheumatoid arthritis: double-blind randomised
controlled trial. Lancet 2004;363:675–81.
11. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al.
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor
alpha monoclonal antibody combined with low-dose weekly methotrexate in
rheumatoid arthritis. Arthritis Rheum 1998;41:1552–63.
12. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven
R, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of
combination therapy with adalimumab plus methotrexate versus methotrexate alone
or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had
not had previous methotrexate treatment. Arthritis Rheum 2006;54:26–37.
13. ENBREL (package insert). Thousand Oaks, CA: Immunex Corporation, 2008.
14. HUMIRA (package insert). North Chicago, IL: Abbott Laboratories, 2008.
15. REMICADE (package insert). Malvern, PA: Centocor, Inc, 2007.
16. Shealy D, Cai A, Lacy E, Nesspor T, Staquet K, Johns L, et al. Characterization of
golimumab (CNTO 148), a novel fully human monoclonal antibody specific for TNF-
alpha (EULAR abstract THU0088). Ann Rheum Dis 2007;66(Suppl II):151.
17. Kay J, Matteson EL, Dasgupta B, Nash P, Durez P, Hall S, et al. Golimumab in
patients with active rheumatoid arthritis despite treatment with methotrexate: a
randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum
2008;58:964–75.
18. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The
American Rheumatism Association 1987 revised criteria for the classification of
rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.
19. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al.
American College of Rheumatology. Preliminary definition of improvementi n
rheumatoid arthritis. Arthritis Rheum 1995;38:727–35.
20. Siegel JN, Zhen BG. Use of the American College of Rheumatology N (ACR-N) index
of improvement in rheumatoid arthritis: argument in favor. Arthritis Rheum
2005;52:1637–41.
21. Prevoo ML, van ’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel
PL. Modified disease activity scores that include twenty-eight-joint counts.
Development and validation in a prospective longitudinal study of patients with
rheumatoid arthritis. Arthritis Rheum 1995;38:44–8.
22. van Riel PL, van Gestel AM, Scott DL. EULAR handbook of clinical assessments in
rheumatoid arthritis. Alphen Aan Den Rijn, The Netherlands: Van Zuiden
Communications, BV, 2000.
23. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in
arthritis. Arthritis Rheum 1980;23:137–45.
24. Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA. Minimum
important difference between patients with rheumatoid arthritis: the patient’s
perspective. J Rheumatol 1993;20:557–60.
25. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, et al.
Clinical response to adalimumab: relationship to anti-adalimumab antibodies and
serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis
2007;66:921–6.
26. Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, et al.
Effects of abatacept in patients with methotrexate-resistant active rheumatoid
arthritis: a randomized trial. Ann Intern Med 2006;144:865–76.
27. Kievit W, Fransen J, Oerlemans AJM, Kuper HH, van der Laar MAFJ, de Rooij
DJRAM, et al. The efficacy of anti-TNF in rheumatoid arthritis, a comparison between
randomised controlled trials and clinical practice. Ann Rheum Dis 2007;66:1473–8.
28. Zink A, Strangfeld A, Schneider M, Herzer P, Hierse F, Stoyanova-Scholz M, et al.
Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an
observational cohort study: comparison of patients according to their eligibility for
major randomized clinical trials. Arthritis Rheum 2006;54:3399–407.
29. Hetland ML, Lindegaard HM, Hansen A, Podenphant J, Unkerskov J, Ringsdal VS, et
al. Do changes in prescription practice in patients with rheumatoid arthritis treated
with biologics affect treatment response and adherence to therapy? Results from the
nationwide Danish Danbio Registry. Ann Rheum Dis 2008;67:1023–6.
30. van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL, et al. Efficacy
and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for
whom previous disease modifying antirheumatic drug treatment has failed. Ann
Rheum Dis 2004;63:508–16.
Extended report
796 Ann Rheum Dis 2009;68:789–796. doi:10.1136/ard.2008.099010